TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12506176
Drug: Concurrent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent bolus cisplatin with radiation (arm B)
Study: 12506176
Drug: Split course
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split course of radiation with concurrent infusional fluorouracil and bolus cisplatin (arm C)
Study: 12506176
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily fractionated radiation (arm A, control)
Study: 2203397
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin during streptokinase infusion (group 1)
Study: 2203397
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin after streptokinase infusion (group 2)
Study: 31531771
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Streptococcus dentisani (n=5)
Study: 31531771
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of Streptococcus dentisani for a week (n=6)
Study: 31531771
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing schedules of Streptococcus dentisani
Study: 28093815
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (NSO) 500 mg twice daily for 4 weeks
Study: 21285160
Drug: SCIO-469 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIO-469 30 mg IR
Study: 21285160
Drug: SCIO-469 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIO-469 60 mg IR
Study: 21285160
Drug: SCIO-469 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIO-469 100 mg ER
Study: 14736573
Drug: Nicotine administered
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine administered by patch (3.5 mg for low-hostility non-smokers, 21 mg for high-hostility smokers)
Study: 14736573
Drug: Nicotine administered
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine administered by patch (21 mg)
Study: 9771059
Drug: Prednisolone pre-treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone pre-treatment
Study: 23860964
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells (MSCs) at a dose of 2 × 10(6) cells/kg for each infusion twice a week for 4 weeks, with the option for weekly infusions for an additional 4 weeks if needed.
Study: 21771568
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg every 21-28 days)
Study: 19155070
Drug: Adherence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence therapy (8 sessions)
Study: 9593789
Drug: Daily chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily chlorambucil
Study: 9593789
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group for first trial)
Study: 9593789
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group for second trial)
Study: 3058874
Drug: 12-week regimen
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week regimen of adjuvant chemotherapy
Study: 3058874
Drug: 36-week regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36-week regimen of adjuvant chemotherapy
Study: 29308522
Drug: Ibuprofen 300mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 300mg, bid for 5 days after scaling and root planing (SRP)
Study: 26094712
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (nurse titrated analgesia)
Study: 23035844
Drug: AC952 Aloe
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC952 Aloe vera inner leaf gel powder
Study: 23035844
Drug: UP780 Aloe
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP780 Aloe vera inner leaf gel powder standardized with 2% aloesin
Study: 20707253
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg plus codeine 60 mg tid for 24 hours (Group A)
Study: 20707253
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg qid for 24 hours (Group B)
Study: 16488952
Drug: DS-MMC (deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-MMC (deep sclerectomy with intraoperative low dose mitomycin C 0.25 mg/ml for 2 minutes)
Study: 15106284
Drug: Sodium enoxaparin
Normalized name: Enoxaparin Sodium
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium enoxaparin administered for 10 days
Study: 15106284
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (corticosteroids, vasoactive agents, multivitamins, and anticoagulants)
Study: 11102254
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg bolus followed by 75 mg per day for 3-12 months) + Aspirin
Study: 11102254
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Ticlopidine
Study: 4062333
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide injection
Study: 4062333
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% betamethasone dipropionate under occlusion
Study: 20149955
Drug: 12-month group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month group behavioral treatment designed to increase autonomy and self-regulation for weight control
Study: 14671145
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist starting on day 1 of stimulation (n = 30)
Study: 14671145
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist starting on day 6 of stimulation (n = 30)
Study: 8636452
Drug: Chlorhexidine diacetate
Normalized name: Chlorhexidine diacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine diacetate gum (20 mg total daily)
Study: 8636452
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gluconate mouthwash (40 mg total daily)
Study: 30643069
Drug: Manipulation combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation combined with biofeedback electrical stimulation treatment for 30 days
Study: 30643069
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation biofeedback therapy
Study: 24972190
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg tid for a mean of 36.6 days
Study: 19416227
Drug: Fluticasone 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 0.005% ointment
Study: 17634259
Drug: CHO+PRO (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+PRO (0.3 g x kg(‐1) protein hydrolysate)
Study: 17634259
Drug: CHO (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (0.3 g x kg(‐1) carbohydrate)
Study: 11437018
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group treatment for depression
Study: 9510453
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of CPAP
Study: 28095544
Drug: Same-day sequential
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day sequential Q-switched Nd:YAG laser and 1565 nm non-ablative fractional laser (SST)
Study: 28095544
Drug: Fractional non-ablative
Normalized name: OMIDUBICEL NON-CULTURED FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional non-ablative laser (NAFL) treatment only
Study: 19392908
Drug: Extended Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended Cognitive Behavioral Therapy (E-CBT)
Study: 19392908
Drug: Extended Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended Nicotine Replacement Therapy (E-NRT)
Study: 12737857
Drug: Rectal adenoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal adenoma
Study: 11876893
Drug: Irradiated drug-containing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated drug-containing porcine-cornea (ofloxacin, acetyl cysteine, reduced glutathione)
Study: 9292758
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (six mugs daily)
Study: 6367413
Drug: verapamil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (0.2 mg/kg total by bolus and by 10-minute infusion)
Study: 27367585
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 10 mg Lutein, 2 mg Zeaxanthin, and 10 mg Meso-zeaxanthin for 12 months
Study: 24440210
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of Ty21a vaccine with anti-helminthic treatment
Study: 24440210
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of Ty21a vaccine without anti-helminthic treatment
Study: 14996676
Drug: Peginterferon-alpha2a, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon-alpha2a, 180 microg/wk for 48 weeks plus standard-dose ribavirin (1000 or 1200 mg/d)
Study: 14996676
Drug: Peginterferon-alpha2a, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon-alpha2a, 180 microg/wk for 24 weeks plus low-dose ribavirin (800 mg/d)
Study: 14996676
Drug: Peginterferon-alpha2a, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon-alpha2a, 180 microg/wk for 48 weeks plus low-dose ribavirin (800 mg/d)
Study: 14996676
Drug: Peginterferon-alpha2a, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon-alpha2a, 180 microg/wk for 24 weeks plus standard-dose ribavirin (1000 or 1200 mg/d)
Study: 8971958
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram of 1,25(OH)2D3 administered orally for 7 days
Study: 8971958
Drug: 0.5 microgram
Normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microgram of 1,25(OH)2D3 administered orally for 7 days
Study: 1737537
Drug: Topical 0.075%
Normalized name: capsaicin topical 0.075% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.075% capsaicin cream (open-label study)
Study: 6393805
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (2 g intramuscular injections at 6-hr intervals)
Study: 7723978
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline injections)
Study: 31596461
Drug: Gabapentin (preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (preoperative 15 mg/kg, postoperative 7.5 mg/kg two times per day for three days)
Study: 28212463
Drug: AZD5423 (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5423 (inhaled selective glucocorticoid receptor modulator)
Study: 28212463
Drug: Reference glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference glucocorticoid receptor agonist (double the approved dose)
Study: 23972320
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (montelukast 4 mg and levocetirizine 2.5 mg/5 ml)
Study: 23972320
Drug: Levocetirizine 2.5
Normalized name: Levocetirizine 2.5mg/5mL Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 2.5 mg/5 ml
Study: 21711959
Drug: Montelukast and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast and Levocetirizine combination
Study: 21711959
Drug: Montelukast and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast and Antihistamine combinations
Study: 11072942
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium butyrate (80 mmol/L, 80 mL/24 h)
Study: 11072942
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium butyrate (after switching from saline)
Study: 8649634
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (40 micrograms at 0, 1, and 3 months)
Study: 1534476
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (0.1 mg of 17 beta-estradiol via dermal patches for days 1 to 21 and oral medroxyprogesterone acetate for days 11 to 21 of a 28-day cycle)
Study: 24271137
Drug: Evacetrapib 1200
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 1200 mg daily for 10 days
Study: 24271137
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg for 1 day (positive control)
Study: 17389552
Drug: PTC124 single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC124 single-dose administration (3 to 200 mg/kg, specifically 50 mg/kg for pharmacokinetics)
Study: 17389552
Drug: PTC124 multiple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC124 multiple-dose administration (10 to 50 mg/kg/dose twice per day for up to 14 days)
Study: 17389552
Drug: PTC124 pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC124 pharmacokinetics
Study: 15786487
Drug: Escitalopram (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (initiated at 10 mg/day, increased to a maximum of 20 mg/day)
Study: 11235922
Drug: Ziprasidone i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone i.m. 10 mg
Study: 11235922
Drug: Ziprasidone i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone i.m. 2 mg
Study: 7921531
Drug: 16 alpha-gitoxin
Normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 alpha-gitoxin (2.5 to 15 mg, i.v. or oral)
Study: 7921531
Drug: 16 alpha-gitoxin
Normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 alpha-gitoxin (5 mg i.v.)
Study: 7921531
Drug: 16 alpha-gitoxin
Normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 alpha-gitoxin (10 mg oral)
Study: 7921531
Drug: 16 alpha-gitoxin
Normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 alpha-gitoxin (7.5 mg)
Study: 7921531
Drug: 16 alpha-gitoxin
Normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 alpha-gitoxin (various doses)
Study: 3048090
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg once daily for 10 days
Study: 3048090
Drug: Amoxicillin 250
Normalized name: amoxicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 250 mg three times daily for 10 days
Study: 29193126
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg azeloprazole sodium
Study: 29193126
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg azeloprazole sodium
Study: 29193126
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg azeloprazole sodium
Study: 29193126
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rabeprazole sodium
Study: 29193126
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rabeprazole sodium
Study: 29193126
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg azeloprazole sodium (before a meal)
Study: 23160722
Drug: Yogurt drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt drink (doogh) fortified with 500 IU vitamin D/250 mL for 12 weeks
Study: 18308250
Drug: Rapid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid treatment (COJEC regimen: cisplatin, vincristine, carboplatin, etoposide, cyclophosphamide)
Study: 18308250
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (OPEC and OJEC regimens: vincristine, cisplatin, etoposide, cyclophosphamide)
Study: 16219350
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of recombinant erythropoietin (r‐EPO) and thalidomide
Study: 10750335
Drug: H 50
Normalized name: INH 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: H 50 mg
Study: 10750335
Drug: H 100
Normalized name: Gentle Touch 100mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: H 100 mg
Study: 9421123
Drug: OME/AMO (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OME/AMO (Omeprazole 2 x 40 mg and Amoxicillin 4 x 500 mg)
Study: 9421123
Drug: OME/AMO/BSC (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OME/AMO/BSC (Omeprazole 2 x 40 mg, Amoxicillin 4 x 500 mg, and Bismuth Subcitrate 4 x 120 mg)
Study: 26312597
Drug: Teriparatide therapy
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide therapy (20 µg twice daily) for 1 week
Study: 26312597
Drug: Teriparatide therapy
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide therapy and Standard treatment (control)
Study: 21498114
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO(3)) ingestion (0.3 g kg(‐1) body mass)
Study: 19140238
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glyceryl trinitrate
Study: 19140238
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vitamin C (placebo)
Study: 17711595
Drug: Elastic compression
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic compression stockings (ECS) worn daily on the DVT-affected leg for 2 years
Study: 17711595
Drug: Placebo (inactive)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive) stockings worn daily on the DVT-affected leg for 2 years
Study: 12752398
Drug: Intramuscular infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular infusion of a combination of bradykinin, serotonin, histamine, and prostaglandin E2
Study: 9821565
Drug: 0.5 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mol/L sodium lactate
Study: 2506844
Drug: Centrophenoxine (CPH)
Normalized name: CETYLPYRIDINIUM CHLORIDE 1.11 g in 13.0 mL TOPICAL SPRAY [CPH Anti-bacterial Breath Mist]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrophenoxine (CPH) 2 g/day for 8 weeks
Study: 2506844
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 8 weeks
Study: 823433
Drug: 3.5% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5% amino acid solution
Study: 6101516
Drug: Propranolol maintained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol maintained until the day of surgery, half the usual dose given 2 hours prior to surgery, and intravenous propranolol administered every four hours postoperatively (group IV, n=19)
Study: 6101516
Drug: No propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No propranolol therapy (group I, n=17)
Study: 28377173
Drug: Alfacalcidol 1
Normalized name: alfacalcidol 1 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 1 μg daily for 4 months
Study: 28377173
Drug: Standard asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard asthma treatment only
Study: 24225560
Drug: L-arginine (ARG;
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (ARG; 0.075 g·kg‐1 body mass)
Study: 9457092
Drug: Active warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active warfarin and active aspirin (WA)
Study: 9457092
Drug: Active warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active warfarin (W)
Study: 9457092
Drug: Active aspirin
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active aspirin (A)
Study: 9457092
Drug: Warfarin or
Normalized name: warfarin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin or aspirin
Study: 7616989
Drug: Zidovudine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (250 mg twice daily)
Study: 201111
Drug: D-thyroxin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-thyroxin (4 mg/die)
Study: 30624885
Drug: Bicyclic RGD
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicyclic RGD peptides (e.g., CT3HPQcT3RGDcT3, CT3HPQCT3RGDcT3, CT3HSQCT3RGDcT3)
Study: 26049181
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d hydrocortisone intravenous infusion lasting for 2 hours (control group)
Study: 26049181
Drug: 8.33 mg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.33 mg/h hydrocortisone per hour with an intravenous pump (research group)
Study: 18586692
Drug: More positive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More positive medication attitudes
Study: 18586692
Drug: Change toward
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change toward more positive medication attitudes